Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Completed
National Cancer Institute (NCI)
Phase 1
1999-05-28
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were
destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the
transplanted cells are rejected by the body's normal tissues. Transplanting donated cells
that have been treated with psoralen may prevent this from happening.
PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and
psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell
transplantation for hematologic cancer.
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Completed
M.D. Anderson Cancer Center
Phase 1
1999-05-28
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were
destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the
transplanted cells are rejected by the body's normal tissues. Transplanting donated cells
that have been treated with psoralen may prevent this from happening.
PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and
psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell
transplantation for hematologic cancer.
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
Completed
Mallinckrodt
Phase 2
2002-06-01
The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX
(ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the
prevention of Graft-versus-Host Disease (GvHD).
Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease
Completed
Mallinckrodt
Phase 2
2002-06-01
The purpose of this study is to determine whether extracorporeal photoimmune therapy with
UVADEX (ECP) added to standard therapy is effective in the treatment of chronic
graft-versus-host disease (GvHD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
